TWENTY ONE CAPITAL INC-CL A (XXI) Stock Fundamental Analysis

NYSE:XXI • US90138L1098

6.4 USD
+0.6 (+10.34%)
At close: Feb 13, 2026
6.55 USD
+0.15 (+2.34%)
After Hours: 2/13/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

XXI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 237 industry peers in the Capital Markets industry. XXI has a bad profitability rating. Also its financial health evaluation is rather negative. XXI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year XXI was profitable.
XXI Yearly Net Income VS EBIT VS OCF VS FCFXXI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 1M 2M 3M

1.2 Ratios

  • The Return On Assets of XXI (2.87%) is comparable to the rest of the industry.
  • XXI's Return On Equity of 2.93% is on the low side compared to the rest of the industry. XXI is outperformed by 67.51% of its industry peers.
Industry RankSector Rank
ROA 2.87%
ROE 2.93%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XXI Yearly ROA, ROE, ROICXXI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 50 100 150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for XXI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XXI Yearly Profit, Operating, Gross MarginsXXI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • XXI has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, XXI has about the same debt to assets ratio.
XXI Yearly Shares OutstandingXXI Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M 10M
XXI Yearly Total Debt VS Total AssetsXXI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • XXI has an Altman-Z score of 1240.68. This indicates that XXI is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of XXI (1240.68) is better than 100.00% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that XXI is not too dependend on debt financing.
  • XXI's Debt to Equity ratio of 0.01 is amongst the best of the industry. XXI outperforms 83.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1240.68
ROIC/WACCN/A
WACCN/A
XXI Yearly LT Debt VS Equity VS FCFXXI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 0.13 indicates that XXI may have some problems paying its short term obligations.
  • XXI's Current ratio of 0.13 is on the low side compared to the rest of the industry. XXI is outperformed by 90.30% of its industry peers.
  • A Quick Ratio of 0.13 indicates that XXI may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.13, XXI is not doing good in the industry: 90.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
XXI Yearly Current Assets VS Current LiabilitesXXI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100K 200K 300K 400K

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • XXI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1309.11%, which is quite impressive.
EPS 1Y (TTM)1309.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • XXI is valuated correctly with a Price/Earnings ratio of 13.33.
  • Compared to the rest of the industry, the Price/Earnings ratio of XXI is on the same level as its industry peers.
  • The average S&P500 Price/Earnings ratio is at 27.19. XXI is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 13.33
Fwd PE N/A
XXI Price Earnings VS Forward Price EarningsXXI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XXI Per share dataXXI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • XXI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TWENTY ONE CAPITAL INC-CL A

NYSE:XXI (2/13/2026, 8:04:00 PM)

After market: 6.55 +0.15 (+2.34%)

6.4

+0.6 (+10.34%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners2.22%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.17B
Revenue(TTM)N/A
Net Income(TTM)3.08M
AnalystsN/A
Price TargetN/A
Short Float %5.18%
Short Ratio1.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 13.33
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 39.67
P/tB 39.67
EV/EBITDA N/A
EPS(TTM)0.48
EY7.5%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.32
Profitability
Industry RankSector Rank
ROA 2.87%
ROE 2.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z 1240.68
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1309.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

TWENTY ONE CAPITAL INC-CL A / XXI FAQ

What is the fundamental rating for XXI stock?

ChartMill assigns a fundamental rating of 2 / 10 to XXI.


What is the valuation status for XXI stock?

ChartMill assigns a valuation rating of 1 / 10 to TWENTY ONE CAPITAL INC-CL A (XXI). This can be considered as Overvalued.


What is the profitability of XXI stock?

TWENTY ONE CAPITAL INC-CL A (XXI) has a profitability rating of 1 / 10.


What is the financial health of TWENTY ONE CAPITAL INC-CL A (XXI) stock?

The financial health rating of TWENTY ONE CAPITAL INC-CL A (XXI) is 3 / 10.